THC Science

Omidenepag
Clinical data
Trade names	Eybelis, Omlonti
Other names	UR-7276, DE-117, Omidenepag isopropyl (JAN JP)
Routes of; administration	Topical eye drops
ATC code	S01EX06 (WHO) ;
Legal status
Legal status	US: ℞-only; Rx-only;
Identifiers
	IUPAC name Propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate;
CAS Number	1187451-41-7; 1187451-19-9;
PubChem CID	44230575; 44230999;
DrugBank	DB15071;
ChemSpider	44210451; 57643658;
UNII	Z95F9F9LU4; G0G0H52U6K;
KEGG	D10965; D10966;
ChEMBL	ChEMBL3707245; ChEMBL4297666;
Chemical and physical data
Formula	C26H28N6O4S
Molar mass	520.61 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)OC(=O)CNC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=N1;
	InChI InChI=1S/C23H22N6O4S/c30-23(31)15-25-22-6-1-4-19(27-22)17-28(34(32,33)21-5-2-11-24-14-21)16-18-7-9-20(10-8-18)29-13-3-12-26-29/h1-14H,15-17H2,(H,25,27)(H,30,31); Key:YHGSTSNEOJUIRN-UHFFFAOYSA-N; ; InChI=1S/C26H28N6O4S/c1-20(2)36-26(33)17-28-25-8-3-6-22(30-25)19-31(37(34,35)24-7-4-13-27-16-24)18-21-9-11-23(12-10-21)32-15-5-14-29-32/h3-16,20H,17-19H2,1-2H3,(H,28,30); Key:VIQCWEGEHRBLAC-UHFFFAOYSA-N;

Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.^[1]^[3]

Omidenepag was approved for medical use in Japan in 2018,^[3] and in the United States in September 2022.^[2]^[4]

Medical uses[edit]

Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.^[1]^[3]

Adverse effects[edit]

The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.^[3]

Pharmacology[edit]

Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag.^[5] Omidenepag is a selective prostaglandin E2 receptor agonist.^[6]^[7]

History[edit]

Omidenepag was developed by Ube Industries and Santen Pharmaceutical.^[3]

References[edit]

^ ^a ^b ^c "Omlonti- omidenepag isopropyl solution/ drops". DailyMed. 30 September 2022. Retrieved 16 October 2022.
^ ^a ^b "Drug Approval Package: Omlonti". U.S. Food and Drug Administration (FDA). 20 October 2022. Retrieved 4 December 2022.
^ ^a ^b ^c ^d ^e ^f Duggan S (December 2018). "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs. 78 (18): 1925–1929. doi:10.1007/s40265-018-1016-1. PMID 30465134. S2CID 53721056.
^ "Santen and UBE Received FDA Approval for Omlonti (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension" (Press release). Santen. 26 September 2022. Retrieved 1 October 2022 – via Business Wire.
^ "Omidenepag isopropyl". DrugCentral. Division of Translational Informatics at University of New Mexico. Archived from the original on 8 January 2022. Retrieved 8 January 2022.
^ Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, et al. (January 2018). "Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent". Investigative Ophthalmology & Visual Science. 59 (1): 145–153. doi:10.1167/iovs.17-22745. PMID 29332128.
^ Ida Y, Hikage F, Umetsu A, Ida H, Ohguro H (September 2020). "Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells". Scientific Reports. 10 (1): 16018. Bibcode:2020NatSR..1016018I. doi:10.1038/s41598-020-72538-x. PMC 7524797. PMID 32994409.

External links[edit]

"Omidenepag". Drug Information Portal. U.S. National Library of Medicine.
"Omidenepag isopropyl". Drug Information Portal. U.S. National Library of Medicine.
"Omidenepag". NCI Thesaurus.
"Omidenepag isopropyl". NCI Thesaurus.

[Omlonti_FDA_label-1] "Omlonti- omidenepag isopropyl solution/ drops". DailyMed. 30 September 2022. Retrieved 16 October 2022.

[Drug_Approval_Package:_Omlonti-2] "Drug Approval Package: Omlonti". U.S. Food and Drug Administration (FDA). 20 October 2022. Retrieved 4 December 2022.

[Duggan-3] ^ ^a ^b ^c ^d ^e ^f Duggan S (December 2018). "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs. 78 (18): 1925–1929. doi:10.1007/s40265-018-1016-1. PMID 30465134. S2CID 53721056.

[4] "Santen and UBE Received FDA Approval for Omlonti (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension" (Press release). Santen. 26 September 2022. Retrieved 1 October 2022 – via Business Wire.

[5] "Omidenepag isopropyl". DrugCentral. Division of Translational Informatics at University of New Mexico. Archived from the original on 8 January 2022. Retrieved 8 January 2022.

[6] Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, et al. (January 2018). "Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent". Investigative Ophthalmology & Visual Science. 59 (1): 145–153. doi:10.1167/iovs.17-22745. PMID 29332128.

[7] Ida Y, Hikage F, Umetsu A, Ida H, Ohguro H (September 2020). "Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells". Scientific Reports. 10 (1): 16018. Bibcode:2020NatSR..1016018I. doi:10.1038/s41598-020-72538-x. PMC 7524797. PMID 32994409.

[1]

[2]

[3]

[4]

[5]

[6]

[7]